Belgium Pharma and Life Sciences Tax Guide

Innovation Deduction (Innovatie-aftrek / Déduction pour Innovation)

• 85% exemption: Qualifying patent and IP income is 85% exempt from corporate tax. Only 15% of the net IP income is included in taxable profit. The effective tax rate on IP income is: (a) for non-SMEs: 25% × 15% = 3.75%, (b) for SMEs on the first €100K: 20% × 15% = 3%. Qualifying IP: patents, copyrighted software (life sciences software, data analytics, bioinformatics tools), supplementary protection certificates (SPCs), and orphan drug designations. The regime follows the OECD modified nexus approach (BEPS Action 5) — the deduction is limited by the nexus ratio (qualifying R&D expenditures / total R&D expenditures × IP income).
• Nexus ratio: The deduction is calculated as: qualifying R&D expenditures / overall R&D expenditures × net IP income × 85%. Outsourced R&D to related parties is subject to a 30% uplift (the "upslift" / "majoration") — the qualifying expenditures can be increased by 30% of the outsourced amount, capped at 30% of total qualifying expenditures without outsourcing. This means that for a pharma company that outsources 100% of its R&D to a third party, the deduction is based on 85% × (1 − outsourcing% + 30% uplift) × IP income.

R&D Tax Credit (Belastingkrediet voor O&O / Crédit d'Impôt pour la R&D)

• Refundable credit: Belgium offers a refundable tax credit for qualifying R&D expenditures (the "belastingkrediet voor onderzoek en ontwikkeling" / "crédit d'impôt pour la recherche et le développement"). The credit is: 20% of qualifying R&D expenses for existing companies, or 33% for new tax residents (companies that have been Belgian tax resident for less than 5 years and have spent at least 15% of their total expenses on R&D in the first 3 years). The credit is refundable — if the credit exceeds the company's tax liability, the excess is paid in cash.
• Qualifying expenses: The credit applies to: (a) R&D personnel costs (wages, social security, pensions), (b) depreciation of R&D equipment and buildings, (c) R&D consumables and materials, (d) subcontractor R&D costs (up to 50% of total qualifying expenses), (e) patent filing and maintenance costs. The credit is available for both fundamental research and applied industrial research.

RD Payroll Withholding Exemption for Researchers

• 80% exemption (Wet Genscher / Loi Genscher): Employers can benefit from an 80% exemption from payroll withholding tax (bedrijfsvoorheffing / précompte professionnel) for qualifying research personnel. The exemption applies to: (a) researchers holding at least a master's degree (or equivalent) in a scientific discipline, (b) PhD researchers, (c) research technicians and engineers directly involved in R&D projects. The employer must be engaged in qualifying R&D (certified by the "Federale Overheidsdienst Economie" / "Service Public Fédéral Économie").
• 25% exemption (additional): A further 25% exemption of payroll withholding tax is available for the first 5 years of employment of a PhD researcher (the "doctoraatsbonus" / "bonus doctorat"). This is in addition to the 80% exemption, bringing the total to approximately 90% for qualifying PhD researchers.
• Application: The employer must apply to the FOD Economie / SPF Économie for certification of the R&D project. The certification confirms that the project meets the Frascati Manual definition of research and experimental development. The certification is valid for 3 years (renewable). The exemption is applied automatically to the payroll withholding return — the employer reduces the amount of bedrijfsvoorheffing to be paid.

Clinical Trials and Pharma-Specific Rules

• Clinical trial income: Income from clinical trials (payments from the sponsor to the investigator/hospital) is generally treated as business income subject to corporate tax. However, if the clinical trial is conducted by a recognised research institution (hospital, university), the income may be exempt under certain conditions (the "social profit" rules). The VAT treatment of clinical trials: (a) payments to the investigator for conducting the trial are subject to VAT (reverse charge if the investigator is in another EU country), (b) payments to healthy volunteers are not subject to VAT.
• R&D premises exemption (Onroerende voorheffing exemption): Buildings used for R&D purposes may qualify for a 5-year exemption from onroerende voorheffing (property tax) in Flanders and Wallonia. The exemption is granted if the building is newly constructed or substantially renovated and is used exclusively for R&D activities. The exemption is applied at the regional level.
• Patent box interaction: Belgian life sciences companies can combine the innovation deduction (85% IP exemption) with the R&D tax credit and the payroll withholding exemption for researchers. The combined benefit can reduce the effective tax rate on IP income to approximately 3–12% (depending on the mix of R&D activities and patent income).

For related reading, see our Corporate Tax Guide →, Cross-Border Tax Guide →, and Hiring Employees Guide →.